Clinical trials: Central Nervous System Metastases
Recurrent Medulloblastoma, Refractory Medulloblastoma
A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)
The purpose of this study is to find out whether 177Lu-DPTA-omburtamab is a safe treatment for children and adolescents with recurrent/refractory medulloblastoma or another type of cancer with CNS metastases.
- Conditions
- Recurrent Medulloblastoma, Refractory Medulloblastoma, CNS Metastases, Central Nervous System Metastasis
- Trial name
- NCT07698899
- Testing
- 25 mCi 177Lu- DTPA-omburtamab
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
Material Balance of [14C]Zorifertinib in Healthy Adult Male Participants in China
This is a single-center, single-dose, open-label, Phase I study to evaluate the mass balance, biotransformation, pharmacokinetic characteristics, excretion pathways, and safety of a single oral 200 mg/5 µCi dose of…
- Trial name
- NCT07620951
- Testing
- [14C]Zorifertinib Oral Formulation
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
HER2-positive Metastatic Breast Cancer, Central Nervous System Metastases
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain.
- Trial name
- NCT03417544
- Testing
- ATEZOLIZUMAB, PERTUZUMAB, TRASTUZUMAB
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Nancy Lin, MD
Central Nervous System (CNS) Metastases, Breast Cancer
A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
Approximately 5-15% breast cancer patients develop brain metastases. Current local treatments (surgery/radiotherapy) are associated with significant complications, and systemic treatments have limited efficacy.
- Trial name
- BCBM006 (NCT07653893)
- Testing
- No Interventions
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Central Nervous System Cancer, Brain Metastases
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months…
- Trial name
- NCT07462507
- Testing
- [C-11]-CS1P1, Brain MRI
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Washington University School of Medicine
Breast Cancer, Central Nervous System Metastases
Predictive Factors for CNS Metastases in Early Breast Cancer Using Liquid Biopsy (AKRA CŽS)
Breast cancer is the most common cancer in women. Although most patients are diagnosed at an early stage and treated with curative intent, some later develop metastases to the central nervous system (CNS), which are associated…
- Trial name
- AKRA CŽS (NCT07447544)
- Testing
- Primary Tumor mRNA Expression Profiling (NGS), Serum Chemokine Quantification (ELISA)
- Where
- Slovenia
- Volunteers
- 22 people
- Sponsor
- Institute of Oncology Ljubljana
EGFR Mutant Advanced Non-small Cell Lung Cancer, Central Nervous System (CNS) Metastases
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
This study is a patient-centered, two-group, three-cohort, multi-center, prospective study to further evaluate the survival benefits and safety of zorifertinib as a first-line treatment in EGFRm+ advanced NSCLC patients with CNS…
- Trial name
- NCT07143045
- Testing
- zorifertinib
- Where
- 34 sites in China
- Volunteers
- 800 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Central Nervous System (CNS) Lesions, Brain Metastases
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
This Phase 2 clinical trial will study RVP-001, a new manganese-based MRI contrast agent, in people who are known to have gadolinium-enhancing central nervous system (CNS) lesions, for example brain tumors or multiple sclerosis.
- Conditions
- Central Nervous System (CNS) Lesions, Brain Metastases, Brain Neoplasms, Brain Neoplasms, Benign
- Trial name
- NCT06322342
- Testing
- RVP-001
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Reveal Pharmaceuticals Inc.
Brain Metastases, CNS Neoplasm
HyperArc Registry Study
The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.
- Conditions
- Brain Metastases, CNS Neoplasm, CNS Disorder, Intracranial
- Trial name
- NCT05270707
- Testing
- Stereotactic radiosurgery
- Where
- 7 sites in United States, Australia and 2 more
- Volunteers
- 968 people
- Sponsor
- Varian, a Siemens Healthineers Company
Neoplasm Metastasis, Central Nervous System Metastases
Whole Brain Radiation Using IMRT for Patients With Brain Metastases
Some cancers can spread, or metastasize, to the brain. When they do, treatment often involves surgery and/or radiation. Optimal treatment of brain metastases would maximize disease control and minimize toxicity (or side effects)…
- Trial name
- NCT02753790
- Testing
- Intensity Modulated Radiotherapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- New Mexico Cancer Research Alliance
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma
Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
This pilot clinical trial studies new ways to monitor the impact of hypofractionated image guided radiation therapy in treating patients with stage IV breast cancer. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma
- Trial name
- NCT01706432
- Testing
- hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Chicago
Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma, Adult Medulloblastoma, Adult Noninfiltrating Astrocytoma
- Trial name
- NCT00019578
- Testing
- Sterotactic radiosurgery
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain Metastases, Adult, Central Nervous System Metastases
Focal Intraoperative Radiotherapy of Brain Metastases
Brain metastases (BM) are the most prevalent tumors of the central nervous system (CNS), with a ratio of 10: 1 in relation to primary tumors.
- Trial name
- NCT03789149
- Testing
- Intraoperative Radiotherapy
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- AC Camargo Cancer Center
Breast Cancer, Brain Metastases
TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases
This is a single arm, open label trial to assess the safety and efficacy of tucatinib in combination with pembrolizumab and trastuzumab for the treatment of HER2+ breast cancer brain metastases (BCBM).
- Conditions
- Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
- Trial name
- TOPAZ (NCT04512261)
- Testing
- Tucatinib, Pembrolizumab, Trastuzumab
- Where
- United States
- Sponsor
- Reva Basho
Non-small Cell Lung Cancer, Leptomeningeal Disease
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC
Brain metastases occurs in up to 50% of patients with EGFR mutant NSCLC. Leptomeningeal disease is a subset of patients with brain metastases for which there remains an unmet need.
- Conditions
- Non-small Cell Lung Cancer, Leptomeningeal Disease, Central Nervous System Metastases
- Trial name
- NCT03711422
- Testing
- Afatinib
- Where
- Singapore
- Volunteers
- 2 people
- Sponsor
- National Cancer Centre, Singapore
Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases
The purpose of this study is to see if capecitabine can be taken safely with different doses of lapatinib in patients with HER-2 positive breast cancer involving brain (brain metastases) and/or in spinal fluid (leptomeningeal…
- Trial name
- NCT02650752
- Testing
- Lapatinib in Tandem With Capecitabine
- Where
- 9 sites in United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System Metastases, HER2-positive Breast Cancer
Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis
This is a phase 1b/2 study to evaluate the safety and clinical activity of the combination of lapatinib, everolimus and capecitabine for the treatment of participants with HER2+ breast cancer with metastases in the brain who have…
- Conditions
- Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01783756
- Testing
- lapatinib ditosylate, everolimus, capecitabine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Central Nervous System (CNS) Metastases, Brain Metastases
Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors
The specific purpose of this study is to obtain data on safety and efficacy of combination chemotherapy with Temozolomide and Topotecan in patients with CNS metastases of solid tumors.
- Trial name
- NCT01736800
- Testing
- Topotecan, Temozolomide
- Where
- 2 sites in United States
- Sponsor
- The Methodist Hospital Research Institute